A comparison of the effects of ABVD and ChlVPP chemotherapeutic protocols for Hodgkin's disease on the spermatozoa fertility indices of male rats
محل انتشار: مجله طب تولید مثل ایران، دوره: 7، شماره: 3
سال انتشار: 1388
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 490
فایل این مقاله در 8 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_IJRM-7-3_004
تاریخ نمایه سازی: 16 شهریور 1395
چکیده مقاله:
Background: Fertility protection is important in young patients with Hodgkin's lymphoma. Objective: The goal of this study was to determine the effects of ABVD and ChlVPPchemotherapeutic protocols for Hodgkin's disease on the spermatozoa fertility indices of male rat. Materials and Methods: After determining tolerance dose of drugs in pilot study, 24male rats were divided to four groups: ABVD (doxorubicin, bleomycine, vinblastin,dacarbazine) group, ChlVPP (chlorambucil, vinblastin, procarbazine, prednisolone) group and two control groups one for each treatment group. One half of the lethal dosefor fifty percent of population was used for treatment of animals in each protocol. Spermatozoa were used for computer- assisted sperm analysis (CASA) and morphologyanalyses. Heads of spermatozoa were counted. Results: Body weight, testis and epididymis weights, spermatozoa number, and liveratio in treated rats were significantly less than their control groups (p<0.05) specifically these parameters in ABVD group was less than ChlVPP group (F= 19.6, p=0.000). Spermatozoa morphology in treated groups were more abnormal than control groups(p<0.05). Evaluation of reproductive system efficacy showed that there was no pregnancy in ABVD group and in ChlVPP group there was only one pregnant female(16.6%). Conclusion: According to this study results, the ChlVPP had fewer side effects thanABVD in tolerance doses on male rats' reproductive system. More clinical trial studies are suggested on Hodgkin's patients. With equal treatment effectiveness, it will be better to use the most reliable and safe treatment especially in young patients.
کلیدواژه ها:
نویسندگان
Lida Mohammad Gholizad
Department of Biology, Science College, Urmia University, Urmia, Iran.
Samad Zare
Department of Biology, Science College, Urmia University, Urmia, Iran.
Vahid Nejati
Department of Biology, Science College, Urmia University, Urmia, Iran.
Ali Eyshi Oskooii
Department of Oncology, Emam Khomeyni Hospital, Urmia Medical Sciences University, Urmia, Iran.